The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Outpatient use of liso-cel in patients with R/R LBCL: real-world data from the CIBMTR registry
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, briefly discusses the findings of an analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, which evaluated the safety and feasibility of outpatient use of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’ve known now for some time that liso-cel, a 4-1BB CD19 targeting CAR T-cell has a differentiated safety profile. One of the questions that has come up as liso-cel has been developed is, is that safety profile consistent with outpatient use? We see less CRS with liso-cel. We see a low rate of neurologic toxicity. So this study specifically looked at the CIBMTR registry to look at that question to really kind of define what was the pattern of use for outpatient liso-cel and how did that contrast with patients receiving it inpatient...
We’ve known now for some time that liso-cel, a 4-1BB CD19 targeting CAR T-cell has a differentiated safety profile. One of the questions that has come up as liso-cel has been developed is, is that safety profile consistent with outpatient use? We see less CRS with liso-cel. We see a low rate of neurologic toxicity. So this study specifically looked at the CIBMTR registry to look at that question to really kind of define what was the pattern of use for outpatient liso-cel and how did that contrast with patients receiving it inpatient.
And what this study concluded was that the efficacy was no different in outpatient, so we can get the same efficacy results. And the safety certainly was no different either and comparable with what we see with inpatient use. Importantly, I think we also defined some of the parameters around which patients might have been subsequently admitted to the hospital. And what we see is, again, that outpatient use is certainly feasible with liso-cel from this data set with similar safety and efficacy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
